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In several families, m ultiple endocrine neoplasia type 
2A (MEN 2A) has been found in association with  
cutaneous lichen amyloidosis. It has been debated, 
however, whether the skin am yloidosis found in MEN 
2A families, localized exclusively in  the interscapular 
area, represents the sam e anomaly as that found in  
autosomal dominant fam ilial cutaneous lichen amy­
loidosis, which is more generalized. W e screened two 
MEN 2A families with associated skin amyloidosis for 
germline mutations in  the R E T  gene responsible for 
the MEN 2A cancer syndrom e, and found the same 
mutation characteristic o f  MEN 2A in both fam ilies.
W e also screened probands from  three pedigrees with  
fam ilial cutaneous lichen  am yloidosis for R E T  m uta­
tions. In none o f  the R E T  coding and flanking in- 
tronic sequences was a m utation  detected . This m ost 
probably indicates that skin am yloidosis found in 
som e MEN 2A fam ilies and fam ilial cutaneous lichen  
am yloidosis are different conditions. Consequently, 
patients with apparent fam ilial cutaneous lichen  
am yloidosis do not appear to be at risk for MEN 2A. 
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C utaneous lichen amyloidosis (CLA) is a rare disorder 
characterized by deposits o f  amyloid in the papillary 
dermis. Sporadic as well as autosomal dominant 
hereditary forms have been documented. Gagel et al 
(1989) reviewed 63 of diese hereditary cases. Here 
we refer to the hereditary form as familial cutaneous lichen 
amyloidosis (familial CLA).
CLA-like skin lesions have also been found in patients with 
multiple endocrine neoplasia type 2A (MEN 2A) (Gagel et al, 1989; 
Nunziata et. al, 1989; Ferrer et al, 1991; Kousseâ' et al, 1991; Chabre 
et al, 1992; Robinson et al, 1992; Pacini et al, 1993). MEN 2A is a
neoplastic syndrome characterized by C~cell hyperplasia, medullary 
thyroid carcinoma, pheochromocytoma, and parathyroid hyperpla­
sia. The disorder is caused by specific germline mutations in the 
R E T  proto-oncogene (Donis-Keller et al, 1993; Mulligan et al,
1993).
Because patients have been found with CLA lesions in several 
MEN 2A families, it has been suggested that patients having 
sporadic or familial CLA should be considered at risk for the MEN 
2A syndrome and therefore should be tested for MEN 2A mutations 
(Nunziata et al, 1989; Ferrer et al, 1991; Chabre et al, 1992). Based
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on the association of both o f these conditions, R E T  gene mutations 
have been thought responsible for the skin amyloidosis found in 
MEN 2A patients. W e therefore screened two MEN 2A families 
with associated CLA and three families with familial CLA for R E T  
germline mutations.
MATERIALS AND METHODS
F a m il ia l  C LA  The three families participating in this study had CLA in at 
least two generations (Fig 1). All affected family members were examined 
by a dermatologist. Light microscopic and electron microscopic evidence of 
amyloid was found in skin biopsy specimens from at least two individuals in 
each o f  the familial CLA families, FCLA-2 and FCLA-3. Although no 
electron microscopic analysis was performed on patient material from family 
FCLA-1, the diagnosis in this family was based on a characteristic clinical 
picture and on histopathologic and immunofluorescence examination of 
skin specimens. In all three families, the CLA lesions were found mainly on 
the arms and legs.
M EN  2A/CLA F am ilie s  Families MEN 2A/CLA-1 and -2 have been 
described before. F ig u re  2 shows the relevant parts of the pedigrees. Family 
MEN 2A/CLA-1 has been reported by KoussefFitf a I (1991), who gave a 
detailed description o f the CLA lesions. Family MEN 2A/CLA-2 has been 
described as family B by Lips et al (1994). Some of the patients in this family 
appeared w ith lesions in the interscapular region only and were clinically 
diagnosed as having CLA upon examination by a dermatologist. Light 
microscopic evaluation o f  biopsy specimens o f  the lesions failed, however, 
to detect amyloid.
S in g le -S tra n d  C o n f o r m a t io n  P o ly m o rp h is m  (SSCP) A nalysis
High-molecular-weight D N A  from patients from families MEN 2A/ 
CLA-1, FCLA-1, FCLA-2, and FCLA-3 was used for SSCP analysis o f  all 20 
R E T  exons. DNA amplification was carried out on 150 ng o f DNA in 1 X 
Super Taq reaction bufFer using 0.125 U  o f Super Taq (HT Biotechnology 
Ltd., Cambridge, UK) in a total volume o f 30 jul containing 20 /iM
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F ig u re  1. P e d ig re e s  o f  fa m ilie s  w ith  fam ilia l  c u ta n e o u s  l ic h e n  
am ylo idosis  (FCLA) in c lu d e d  in  th is  s tu d y . Solid symbols indicate 
individuals affected with CLA,
deoxycitidine triphosphate (dCTP), 200 ¡jl M  deoxyadenosine triphosphate/ 
thymidine triphosphatc/guanosine triphosphate, and 1 /xCi o f [a-' PJdCTP, 
The polymerase chain reaction (PCR) consisted of 30 cycles of 92°C for 
40 s, 72°C for 60 s, and another 60 s for annealing at the appropriate 
temperature. T a b le  I  lists the primers (1 00 ng of each primer) used for each 
exon of the R E T  gene, the annealing temperature, and the restriction 
enzymes used when relatively long P C R  products were obtained. Electro­
phoresis was carried out in a 6% polyacrylamide gel under at least two 
different conditions. Glycerol concentrations used were 0%, 5%, or 10%, at 
4°C, 20°C, or 30°C, respectively. W e also used Mutation Detection 
Enhancer gel solution (At-Biochem, Malvern, PA) as a replacement for 
acrylamide and glycerol and ran the gels a t30°C  in 0.5 X Tris-borate buffer 
at a maximum o f 1750 V and 60 W  in a temperature-regulated LKB 2010 
Macrophore electrophoresis unit (Uppsala, Sweden).
P o ly m o rp h ism s  in  the  R E T  G e n e  Intragenic R E T  polymorphisms (see 
T ab le  II) were analyzed by carrying out digestions with the restriction 
enzymes listed or, in the case o f exon 18, by SSCP analysis,
S e q u e n c e  A nalysis For all families, sequence analysis was carried out on 
exons 10 and 11, which are known to account for more than 95% o f the 
mutations found in MEN 2A (Mulligan et aU 1994; Schuffenecker et 
1994). In addition, all SSCP variants observed were sequenced. For SSCP 
and sequence analysis, the same primer sets were used. For sequence 
analysis, however, one o f the primers o f each set was biotinylated. DNA 
amplification was carried out as described earlier. P C R  products were 
separated in a 2% low melting point agarose gel. After cthidium bromide 
staining, bands were cut out and isolated with the Sephaglas BandPrep kit 
(Pharmacia Biotech, Uppsala, Sweden). The two single strands were 
separated using Dynal beads (DYNAL AS, Oslo, Norway). They were 
sequenced with the T7 sequencing kit (Pharmacia Biotech) and 
[a -32P]dCTP. A 6% sequencing gel was used for electrophoresis.
RESULTS
R E T  M utation Screening in MEN 2A/CLA Fam ilies A
search for mutations throughout the entire R E T  gene by means of 
SSCP revealed in one family (MEN 2A/CLA-1) a conformation 
variant in exon 11 in all affected family members (MEN 2A and 
MEN 2A/CLA patients). Upon sequence analysis, this appeared to 
be caused by transition T1900—>C, resulting in the substitution of 
an arginine for a cysteine at codon 634 (Cys634—>Arg) (Fig 3).
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F ig u re  2. P ed ig rees  o f  families w ith  m u ltip le  endocrine  n eo p las ia  
type 2A (MEN 2A) and cutaneous lich en  am yloidosis (CLA) in ­
c lu d ed  in  this study. Solid symbols indicate individuals affected with MEN 
2A; shaded symbols show individuals affected with both MEN 2A and CLA. 
The numbers in pedigree 1 correspond to those of F ig  4,
Sequence analysis of exons 10 and 11 of the R E T  gene showed 
the same mutation, T1900—>C, in family MEN 2 A/CLA-2 in all 
affected family members (MEN 2A  and MEN 2A/CLA patients). 
Confirmation o f the mutation was possible, as this mutation creates 
a Hlial site. Exon-11 alleles with the mutation should have an extra 
Hlial site, giving rise to a PCR product that is 60 bp shorter after 
digestion. Figure 4 shows restriction analysis of exon 11 for nine 
individuals from family MEN 2A/CLA-1. All affected persons 
indeed showed two bands, the wild-type and the 60-bp-shorter 
mutant band, whereas nonaffected persons did not have the restric­
tion site and showed only the wild-type band.
R E T  M utation Screening in Familial CLA Families SSCP 
analysis of all exons of the R E T  gene did not show a causative R E T  
mutation, nor did sequence analysis of exons 10 and 11.
H aplotyping Using Intragenic Polymorphisms All families 
were haplo typed for all of the intragenic markers listed in Table II. 
No specific polymorphism seemed to co-segregate with the familial 
CLA or MEN 2A/CLA phenotypes (data not shown).
DISCUSSION
Phenotypic diversity due to mutations affecting different domains of 
a gene product is a frequent phenomenon known as allelic heter­
ogeneity. The R E T  gene is a well-known example. Base-pair 
substitutions affecting one of five highly conserved cysteine residues 
in the extracellular part of the protein are associated with MEN 2A 
and familial medullary thyroid carcinoma (Mulligan et al, 1994; 
Schuffenecker et rt/, 1994). Furthermore, a missense mutation 
substituting threonine for methionine at codon 918 in the tyrosine 
kinase domain of the protein has been found to be uniquely 
associated with MEN 2B (Carlson et al, 1994; Eng et al, 1994; 
Hofstra et al, 1994). Mutations throughout the gene of one of the 
two alleles, presumably leading to inactivation of the protein, have 
been found responsible for a proportion of patients suffering from 
Hirschsprung disease (Edery et al, 1994; Romeo et al, 1994). The 
combined occurrence of both MEN 2A and CLA in some families
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Table I. Primers U sed in Single-Strand C onform ation Polym orphism  and Sequence Analysis o f  the
RET  P ro to -O n cogen ert
Exon
Number Forward Primer Reverse Primer
Annealing
Temperature
(°C)
Length
(bp)
Restriction
Enzyme
1 5 '-g a g t g c c c c g g a a c g t g c g t -3' 5'CGCGTGCCCACGGCAAACAG-3' 68 166
2 5 '-CCATATTCTC A CCATCCCTC-3 ' 5 ' -AGTGTC AGCGGCTGTG ATA A-3 ' 58 387 5 ítm3 A
3 5 '-g g a c c a g g g t t t a c a c c a g c -3' 5'-G CTTG TG TCA A G G G CTCG CA -3' 58 466 Snidi
4 5'-CCTTCCCGAGGAAACGGCT-3' 5 ' -CGAACTGTGGCCGGAGACAG-31 58 423 Bstcll
5 5'-CCTAAGGTCTCTGGTTTTGG-3 ' 5 ' -AAG A G CG A CCA CCTC ATTTC-3 ' 50 329 A val
6 5 ' -C ATG AGG AAGCAGCC AG A G C-3 ' 5 '-A G T G T C A C C T G C C TC C C T G T-3 ' 57 333 Hcielll
7 5'-CTGGCTAAGGTGTTCCCCTG-3 ' 5 '-CCAG GCTCCAGAAGCTCCCA-3 ' 60 346 BatnHl
8 5 '-GCTGGTGCTGTTCCCTGTCC-3 ' 5 ' -C C T C C C T T  GGGCGTTTCCAG-3 ' 62 239
9 5'-AGTCTGCTGTGTGTCCTG-3 ' 5 '-C C A TG C C C TG A TTA A A C C -3 'G 50 158
10 5'-GAGGCTGAGTGGGCTACGTC-3' 5 '-AGACCTCTGTGGGGCTGGGA-3 ' 61 199
11 5 ' -CTCTGCGGTGCC AAGCCTC A-37 5 '-T C T G T C T C C C C A G C T C G C C T -3 ' 62 375 Slttl
12 5 '-G CC TTC TTCCTCCC TG TC AT-3 ' 5 ' -GAG A C TC C C C  AGGGCACTGT-3 ' 60 267 M a d
13 5'-AACTTGGGGAAGGCGTGCA-3' 5 ' - A G A A C AG G G C T GT AT G G A G C -31 57 277 Aval
14 5'-AAGACCCAAGCTGCCTGACC-3' 5 '-CTG G G TG CAG A G CCATA TG C-3' 60 294 A va il
15 5'-TGACCGCTGCTGCCTGCCAT-3' 5 '-G CTTCC C A A G G A C TG C CTG C-3 ' 61 251
16 5'-AGGGATAGGGCCTGGGCTTC-3' 5 '-TAACCTCCA CCCCA AGA GA G-3' 58 192
17 5'-AGCCACTCACTGGTCCTTCA-3 ' 5 ' -ATG GGG AG GG AATGCACAC A-3 ' 57 240
18 5'-CTGGCCCTGCTTGGATCATA-3 ' 5'~CAGCTTGTGGGAATTGGACC~3' 60 176
19 5'-TAGTTGTGGCACATGGCTTG-3 ' 5 '-G AGAGGAAGGAT AGTGCAGA-3 ' 59 260 A val
20 5'-CAAAGGGAGTTTTGCCAAGG~3' 5 ' - GCCGGT A G A CTTTCC  ATTCT-3 ' 56 311 HcoRV
1 PCR was done for amplification o f  each o f  the 20 exons. T he restriction enzymes indicated were used if P C R  products were longer than 250 bp. Exons 1 and 4 needed 10% 
dimethylsulfoxide in the reaction buffer.
and patients might be associated with specific R E T  mutations. We 
therefore analyzed two families. In patients of one of these, MEN 
2A/CLA-1, the presence of amyloid could be clearly demonstrated. 
Amyloid could not be demonstrated in specimens from the lesions 
of the patients from the other family. Because this is not a consistent 
feature of presumed CLA patients in previously reported MEN 
2A/CLA families, however, and because all lesions were limited to 
the interscapular region, which is generally considered characteris­
tic for the association of MEN 2A and CLA, family MEN 2A/ 
CLA-2 was also included in this study (Gagel et al, 1989; Nunziata 
et al, 1989; Ferrer et al, 1991; Kousseff et <tl, 1991; Chabre et al, 
1992; Robinson et al, 1992; Pacini et al, 1993). In the two families, 
we found the same R E T  mutation in codon 634 (Cys634~>Arg). 
The mutation was present in all MEN 2A patients, some of whom 
also had CLA. A Cys634—>Tyr mutation (G1901—>A) has been 
reported previously in another family with MEN 2A and CLA 
(Ceccherini et al, 1994b). Although all the mutations affect codon 
634, different amino acid substitutions result. The mutations found, 
notably Cys634—»Arg, also occur frequently in MEN 2A families 
without CLA lesions. Although an association between MEN 
2A/CLA and mutations in codon 634 may be postulated, the 
above-mentioned arguments make it hard to suggest a correlation 
between a specific R E T  mutation and the MEN 2A/CLA pheno­
type.
It might be suggested that the joint occurrence o f MEN 2 A and 
CLA would be due to the interaction of an apparently noncausative 
polymorphism and a disease-causing mutation, as has been de­
scribed for the prion gene (Goldfarb et al, 1992). In the R E T  gene, 
several common noncausative polymorphisms have been found
(Table II; Ceccherini et al, 1994a). None of the polymorphisms, 
however, seemed to co-segregate with the MEN 2A/CLA pheno­
type. Thus, for an explanation of the intrafamilial phenotypic 
variability, it may be necessary to look beyond the mutational- 
polymorphic genotype. Differential handling of the gene product by 
the paracrine growth mechanism of a particular individual may alter 
the pathogenesis of the condition and cause pleiotropy o f the 
phenotype (KoussefF et al, 1991; Kousseff, 1992).
A search for R E T  mutations in patients from three “CLA only” 
families did not reveal a mutation other than already known 
noncausative polymorphisms. W e also looked for possible co­
segregation of these intragenic polymorphisms with the cutaneous 
phenotype in these families, but were unsuccessful. W e therefore 
conclude that R E T  is not involved in these cases of familial CLA.
Our findings raise the question of whether the CLA found in 
MEN 2A  and familial CLA are etiologically similar conditions. 
Clinically, there is a distinction in the affected sites. In MEN 2A 
patients, skin lesions are always found in the interscapular region, 
whereas in familial CLA patients, skin lesions are more generalized 
(Robinson et al, 1992). Dysfunction of the R E T  gene, which in 
developing mice is expressed in the peripheral nervous system 
(Scliuchardt et al, 1.994), might lead to pruritus and subsequently to 
scratching and degeneration o f keratinocytes. It has been suggested 
that prolonged mechanical friction may produce a macular amy­
loidosis, or “friction amyloidosis” (Wong and Lin, 1988; Robinson 
et al, 1992). Because many chronic pruritic skin conditions do not 
show skin amyloidosis, however, this etiologic model might be an 
oversimplification.
The current results lend support to the idea that skin lesions in
Table II. N oncausative N u cleotid e Changes D etec ted  in the C oding Sequence o f  R E V 1
Nucleotide Amino Acid Restriction Controls Allele 1
Exon Change Substitution Site Changed** Tested Frequency
2 GCG—>GCA Ala 45 Engl (+ ) 52 0.71
3 GTC—»GTA Val 125 A ft o il ( - )  49 0.98 
7 GCG—»GCA Ala 432 Bsm l (+ )  45 0.29
11 GGT—»AGT Gly 691—»Ser Banl ( - )  53 0.79
13 CTT-hvCTG Leu 769 Taql ( - )  46 0.74
15 T C C -^T C G  Ser 904 R sal (+ )  48 0.21
18 C G C ^ T G C  Arg982—>Cys 90 0.98
" Ceccherini et al, 1994.
b — , Loss o f the mentioned restriction site; H-, gain o f  the mentioned restriction site.
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F ig u re  3. P a r t ia l  s c q u c n c c  analysis  o f  exon  11 in  a n  affec ted  
m e m b e r  o f  fa m ily  M E N  2A/CLA-1. Shown is the relevant part o f  the 
sequence containing the Cys634—*Arg mutation.
familial CLA and MEN 2A/CLA patients are different from genetic, 
clinical, and ctiologic points of view. Consequently, familial CLA 
patients do not appear to be at risk for MEN 2A. To settle this issue 
definitively, however, more data are needed. Mainly for this 
reason, it may still be reasonable for physicians of (apparent) 
familial CLA patients to have their patients screened for R E T  
mutations.
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F ig u re  4. H h à l  r e s t r ic t io n  p a t t e r n s  o f  ex o n  11 in  th e  M EN 2A/ 
C LA -1 fam ily  m e m b e rs  e x a m in e d .  The numbers correspond to those of 
F ig  2. Affected individuals show two bands because o f  an extra HhaI site.
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